CytomX Therapeutics, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $10.3M | $663.0K | $6.0M | $18.7M | $50.9M | $38.1M | $33.4M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $17.6M | $19.2M | $21.2M | $15.3M | $13.3M | $18.9M | $14.8M | $21.4M |
| SG&A Expense | $7.6M | $10.7M | $7.4M | $6.4M | $6.6M | $9.4M | $5.6M | $8.0M |
| Operating Income | $-23.8M | $-19.7M | $-27.9M | $-15.8M | $-1.3M | $22.6M | $17.7M | $4.1M |
| Operating Margin | -1,677.1% | -191.8% | -4,212.8% | -264.4% | -6.9% | 44.4% | 46.4% | 12.3% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-20.6M | $-18.2M | $-26.5M | $-14.2M | $-91.0K | $23.6M | $18.9M | $5.8M |
| Income Tax Expense | $60.0K | $59.0K | $55.0K | $58.0K | $63.0K | $62.0K | $63.0K | $61.0K |
| Net Income | $-20.7M | $-18.2M | $-26.5M | $-14.2M | $-154.0K | $23.5M | $18.9M | $5.7M |
| Net Margin | -1,457.4% | -177.9% | -3,998.5% | -238.6% | -0.8% | 46.2% | 49.6% | 17.2% |
| EPS (Basic) | $-0.09 | $-0.10 | $-0.33 | $-0.09 | $0.00 | $0.27 | $0.22 | $0.07 |
| EPS (Diluted) | $-0.09 | $-0.10 | $-0.33 | $-0.09 | $0.00 | $0.27 | $0.22 | $0.07 |
| Shares Outstanding (Basic) | 218.9M | 177.3M | 137.9M | 165.0M | 129.1M | 87.1M | 84.4M | 85.1M |
| Shares Outstanding (Diluted) | 218.9M | 177.3M | 137.9M | 165.0M | 129.1M | 87.2M | 84.7M | 85.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |